GTBP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.627

Low

8.00

Averages

8.00

High

8.00

Current: 0.627

Low

8.00

Averages

8.00

High

8.00

Roth Capital

Buy

downgrade

$11 -> $8

2025-11-17

Reason

Roth Capital

Price Target

$11 -> $8

2025-11-17

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on GT Biopharma to $8 from $11 and keeps a Buy rating on the shares. GT Biopharma closed Q3 with $2.6M in cash, sufficient to fund operations into 1Q26, the analyst tells investors in a research note. The company is advancing a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33+ hematologic malignancies, with initial data expected in 1Q26, and has resumed preclinical development of GTB-5550 for B7H3+ solid tumors, targeting an IND submission by YE25/1Q26.

Valuation Metrics

The current forward P/E ratio for GT Biopharma Inc (GTBP.O) is -0.67, compared to its 5-year average forward P/E of -3.23. For a more detailed relative valuation and DCF analysis to assess GT Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.23

Current PE

-0.67

Overvalued PE

0.65

Undervalued PE

-7.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GTBP News & Events

Events Timeline

No data

News

3.5

12-15Globenewswire

Ventripoint Partners with Nisga'a to Enhance Cardiac Diagnostics in Remote Areas

3.5

12-15Newsfilter

Ventripoint Partners with Nisga'a to Enhance Cardiac Diagnostics Accessibility

9.0

12-11Newsfilter

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4

People Also Watch

Frequently Asked Questions

What is GT Biopharma Inc (GTBP) stock price today?

The current price of GTBP is 0.6271 USD — it has decreased -5 % in the last trading day.

What is GT Biopharma Inc (GTBP)'s business?

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

What is the price predicton of GTBP Stock?

What is GT Biopharma Inc (GTBP)'s revenue for the last quarter?

GT Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is GT Biopharma Inc (GTBP)'s earnings per share (EPS) for the last quarter?

GT Biopharma Inc. EPS for the last quarter amounts to -0.83 USD, decreased -45.75 % YoY.

What changes have occurred in the market's expectations for GT Biopharma Inc (GTBP)'s fundamentals?

The market is revising No Change the revenue expectations for GT Biopharma, Inc. (GTBP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -23.99%.

How many employees does GT Biopharma Inc (GTBP). have?

GT Biopharma Inc (GTBP) has 1 emplpoyees as of December 16 2025.

What is GT Biopharma Inc (GTBP) market cap?

Today GTBP has the market capitalization of 6.67M USD.